Impact of race-based spirometry equations on guideline-based asthma management in clinical trials
Journal of Allergy and Clinical Immunology · 2025
DOI: 10.1016/j.jaci.2025.08.012 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025. Verfasst von Cynthia M Visness und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rho Inc, Durham, NC. Electronic address: cindy_visness@rhoworld.com. Hauptthemen laut MEDLINE: Asthma, Spirometry. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: The American Thoracic Society recently recommended that race- and ethnicity-specific equations for spirometry be replaced with race-neutral equations. This change could have implications for asthma management. OBJECTIVE: Our aim was to examine the effect of race-specific versus race-neutral spirometry reference equations on the resultant guideline-directed asthma therapy in a study population with a high proportion of Black children. METHODS: We pooled and harmonized data on 2076 children and adolescents across 4 Inner-City Asthma Consortium studies that had all used a computer-asssisted algorithm for management of asthma medication. The asthma control level was recalculated, first by using the percent predicted FEV1 values derived from the 2012 race-specific equations and then by using those derived from the Global Lung Initiative GLI Global race-neutral equations. The calculated control level was then used to determine the recommendation for treatment step changes. RESULTS: Among urban Black children not already at the highest recommended inhaled corticosteroid doses, 18% would have been assigned a higher medication step at study entry when using the race-neutral rather than race-specific reference equations to assess asthma control. A very small number of children in other race or ethnicity groups had a recommendation for a higher medication step. CONCLUSION: The transition to use of race-neutral values for measures of lung function has the potential to reduce racial bias in diagnosing and treating asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rho Inc, Durham, NC. Electronic address: cindy_visness@rhoworld.com.
- University of Wisconsin School of Medicine and Public Health, Madison, Wis.
- National Institute of Allergy and Infectious Diseases, Rockville, Md.
- Rho Inc, Durham, NC.
Förderung
- NIAID NIH HHS
- National Institutes of Health National Institute of Allergy and Infectious Diseases
- National Institutes of Health
Zitieren
APA
Visness, C. M., Sorkness, C. A., Sorkness, R., Gergen, P. J., Nodzenski, M., Jackson, D. J., & National Institute of Allergy and Infectious Diseases–sponsored Childhood Asthma in Urban Settings Network (2025). Impact of race-based spirometry equations on guideline-based asthma management in clinical trials. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2025.08.012
Vancouver
Visness CM, Sorkness CA, Sorkness R, Gergen PJ, Nodzenski M, Jackson DJ, et al. Impact of race-based spirometry equations on guideline-based asthma management in clinical trials. Journal of Allergy and Clinical Immunology. 2025. doi:10.1016/j.jaci.2025.08.012
BibTeX
@article{Visness2025,
author = {Visness, Cynthia M and Sorkness, Christine A and Sorkness, Ronald and Gergen, Peter J and Nodzenski, Michael and Jackson, Daniel J and National Institute of Allergy and Infectious Diseases–sponsored Childhood Asthma in Urban Settings Network, National Institute of Allergy and Infectious Diseases–sponsored Childhood Asthma in Urban Settings Network},
title = {Impact of race-based spirometry equations on guideline-based asthma management in clinical trials},
journal = {Journal of Allergy and Clinical Immunology},
year = {2025},
doi = {10.1016/j.jaci.2025.08.012}
}
EUVIMED